CANCER:

Myelodysplastic Syndrome

No biomarker No biomarker	Myelodysplastic Syndrome MDS	venetoclax Sensitive: B - Late Trials Roche Press Release - 1 week
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	APR-246 Sensitive: B - Late Trials Aprea Press Release - 1 week
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials Br J Haematol - 1 week
ASXL1 deletion ASXL1 deletion	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials Br J Haematol - 1 week
No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine/cedazuridine Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A1 - Approval
Chr del(5q) Chr del(5q)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	azacitidine Sensitive: A1 - Approval
No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine Sensitive: A1 - Approval
PDGFRA rearrangement PDGFRA rearrangement	Myelodysplastic Syndrome MDS	imatinib Sensitive: A1 - Approval
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline
No biomarker No biomarker	Myelodysplastic Syndrome MDS	Hu5F9-G4 Sensitive: B - Late Trials
DNMT3A mutation + SF3B1 mutation DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	MLN4924 Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials
Chr del(5)(q31) Chr del(5)(q31)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials
No biomarker No biomarker	Myelodysplastic Syndrome MDS	Hypomethylating agent + MBG453 Sensitive: B - Late Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	CB-839 Sensitive: C2 – Inclusion Criteria
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	ARO-002 Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	decitabine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C2 – Inclusion Criteria
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	enasidenib Sensitive: C2 – Inclusion Criteria
MECOM mutation + KDM6B mutation MECOM mutation + KDM6B mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials
MECOM mutation + KDM6A mutation MECOM mutation + KDM6A mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
BNIP3L elevation BNIP3L elevation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
LDHA elevation LDHA elevation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
HIF1A overexpression HIF1A overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
PIK3CD mutation PIK3CD mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials
PLCG2 mutation PLCG2 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials
AKT3 mutation AKT3 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials
TMB-H TMB-H	Myelodysplastic Syndrome MDS	Immunotherapy Sensitive: C3 – Early Trials
SF3B1 K700E SF3B1 K700E	Myelodysplastic Syndrome MDS	Hypomethylating agent Sensitive: C3 – Early Trials
SF3B1 mutation + Chr del(5q) SF3B1 mutation + Chr del(5q)	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 mutation Chr del(20q) + ASXL1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 deletion Chr del(20q) + ASXL1 deletion	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
U2AF1 mutation U2AF1 mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials
NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	decitabine Sensitive: C3 – Early Trials
RRM1 underexpression RRM1 underexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
Chr del(5q) + TP53 expression Chr del(5q) + TP53 expression	Myelodysplastic Syndrome MDS	lenalidomide Resistant: C3 – Early Trials
Chr del(5)(q31.1) Chr del(5)(q31.1)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: C3 – Early Trials
EZH2 mutation EZH2 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C3 – Early Trials
SLFN11 expression SLFN11 expression	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials
ANG elevation ANG elevation	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials
AXL elevation AXL elevation	Myelodysplastic Syndrome MDS	BGB324 Sensitive: C3 – Early Trials
JDP2 overexpression JDP2 overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
SPI1 overexpression SPI1 overexpression	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C3 – Early Trials
Chr del(17p) Chr del(17p)	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
NPM1 mutation NPM1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
SETBP1 mutation SETBP1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials
IDH1 mutation IDH1 mutation	Myelodysplastic Syndrome MDS	venetoclax + ivosidenib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	MBG453 Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C4 – Case Studies
BCR-ABL1 fusion BCR-ABL1 fusion	Myelodysplastic Syndrome MDS	imatinib Sensitive: C4 – Case Studies
PCM1-PDGFRB fusion PCM1-PDGFRB fusion	Myelodysplastic Syndrome MDS	imatinib Sensitive: C4 – Case Studies
PAN3-PSMA2 fusion PAN3-PSMA2 fusion	Myelodysplastic Syndrome MDS	decitabine Sensitive: C4 – Case Studies
MCL1 expression MCL1 expression	Myelodysplastic Syndrome MDS	DSP-2033 Sensitive: D – Preclinical

Myelodysplastic Syndrome

Associations(76)

Associations
(76)